Abstract

Intramuscular injections of botulinum toxin block pre-synaptic cholinergic release at neuromuscular junctions producing a temporary paralysis of affected motor units. There is increasing evidence, however, that the effects are not restricted to the periphery and can alter the central excitability of the motoneurones at the spinal level. This includes increases in input resistance, decreases in rheobase currents for action potentials and prolongations of the post-spike after-hyperpolarization. The aim of our experiments was to investigate possible anatomical explanations for these changes. Unilateral injections of Botulinum toxin A mixed with a tracer were made into the gastrocnemius muscle of adult rats and contralateral tracer only injections provided controls. Immunohistochemistry for Ankyrin G and the vesicular acetylcholine transporter labelled axon initial segments and cholinergic C-boutons on traced motoneurones at 2 weeks post-injection. Soma size was not affected by the toxin; however, axon initial segments were 5.1% longer and 13.6% further from the soma which could explain reductions in rheobase. Finally, there was a reduction in surface area (18.6%) and volume (12.8%) but not frequency of C-boutons on treated motoneurones potentially explaining prolongations of the after-hyperpolarization. Botulinum Toxin A therefore affects central anatomical structures controlling or modulating motoneurone excitability explaining previously observed excitability changes.

Highlights

  • Botulinum neurotoxin type-A (BoNT/A) is one of the most dangerous toxins known to man, yet it is being increasingly used, both cosmetically and clinically, to produce long lasting paralysis of specific muscles

  • To determine that mixing the BoNT/A with tracer did not impair its effects, in 3 additional rats we recorded the maximal Compound Muscle Action Potential (CMAP) from the gastrocnemius muscles before and after bilateral injections of BoNT/A with Cholera toxin subunit B (CTB) mixed with the BoNT/A on one side only

  • By 4 days post-injection a drastic reduction in CMAP amplitude was observed on both sides (>75%) regardless of whether the BoNT/A had been mixed with tracer or not (Fig. 1b) confirming that CTB did not impair the ability of the BoNT/A to block neuromuscular transmission

Read more

Summary

Introduction

Botulinum neurotoxin type-A (BoNT/A) is one of the most dangerous toxins known to man, yet it is being increasingly used, both cosmetically and clinically, to produce long lasting paralysis of specific muscles. The soma size measured with this method was still not significantly different between the BoNT/A treated side and the control side when analysed by cell (Mann Whitney: U = 0.9993, P = 0.0999, Fig 1e) or using the mean per animal (Wilcoxon signed ranks test, n = 7 rats, P > 0.999).

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call